CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities
Net loss	$ (4,088,562)	$ (3,904,771)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	119,320	126,781
Stock-based compensation expense	177,309	200,067
Change in fair value of derivative financial instruments—warrants	(2,107)	9,761
Release of clinical trial funding commitment	293,017	70,487
Changes in operating assets and liabilities:
Other assets	1,206	15,725
Accounts receivable and unbilled receivable	97,048	52,079
Prepaid expenses	55,506	179,691
Operating lease right-of-use assets	79,796	73,188
Accounts payable and accrued expenses	88,283	3,635
Operating lease liabilities	(206,129)	(186,689)
Other liabilities	10,676	0
Net cash used in operating activities	(3,374,637)	(3,360,046)
Investing activities:
Capital expenditures	0	(5,274)
Net cash used in investing activities	0	(5,274)
Financing activities:
Proceeds from sales of common stock and warrants	1,000,001	0
Costs related to the clinical trial funding commitment	0	(40,000)
Proceeds from exercise of warrants	1,456,369	3,282,266
Net cash provided by financing activities	2,456,370	3,242,266
Net change in cash and cash equivalents	(918,267)	(123,054)
Cash and cash equivalents—Beginning of period	10,195,292	11,453,133
Cash and cash equivalents—End of period	9,277,025	11,330,079
Supplementary disclosure of cash flow activity:
Cash paid for taxes	800	800
Supplemental disclosure of non-cash investing and financing activities:
Preferred stock dividend payable on Series A Convertible Preferred Stock	6,060	6,060
Deemed dividend recognized for beneficial conversion features of Series C Convertible Preferred Stock issuance	0	268,269
Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment	$ 0	$ 1,675,000